Enhancing exposure of protein therapeutics

Drug Discovery Today: Technologies

Volumn 3, Issue 1, 2006, Pages 87-94

  Beals, John M ^a   Shanafelt, Armen B ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ASPARAGINASE MACROGOL; BLOOD CLOTTING FACTOR 8; ETANERCEPT; FC RECEPTOR; GENE PRODUCT; GLUCAGON LIKE PEPTIDE 1; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; INCRETIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; INTERLEUKIN 2; LENTE; MACROGOL; MICROSPHERE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; POLYMER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG;

ACROMEGALY; ACYLATION; CONJUGATION; CONTROLLED RELEASE FORMULATION; CRYSTALLIZATION; DRUG ADMINISTRATION ROUTE; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG QUALITY; DRUG SAFETY; DWARFISM; ENDOCYTOSIS; GELATION; GENE THERAPY; GENETIC ENGINEERING; GLYCOSYLATION; HEMOPHILIA; HUMAN; HYDROPHOBICITY; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CLEARANCE; LIVER CLEARANCE; PRECIPITATION; PROTEIN DEGRADATION; PROTEIN PROCESSING; RECOMBINANT DNA TECHNOLOGY; REVIEW; SUSTAINED DRUG RELEASE;

EID: 33645990260     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2006.03.001     Document Type: Review

References (47)

1. Bliss M. Discovery of Insulin (1982), University of Chicago, Chicago
2. Brange J., et al. Galenics of Insulin: The Physico-chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations (1987), Springer-Verlag, Berlin
3. Mohler K.M., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151 (1993) 1548-1561
4. Lobo E.D., et al. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93 (2004) 2645-2668
5. Yeh P., et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc. Natl. Acad. Sci. U S A 89 (1992) 1904-1908
6. Waldmann T.A. In: Rosenoer V.M., et al. (Ed). Albumin Structure, Function and Uses (1977), Pergamon Press, Oxford 255-273
7. Sinclair A.M., and Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94 (2005) 1626-1635
8. Elliott S., et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp. Hematol. 32 (2004) 1146-1155
9. Drickamer K., and Taylor M.E. Evolving views of protein glycosylation. Trends Biochem. Sci. 23 (1998) 321-324
10. Drickamer K., and Taylor M.E. Biology of animal lectins. Annu. Rev. Cell Biol. 9 (1993) 237-264
11. Havelund S., et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 21 (2004) 1498-1504
12. Hordern S.V.M., and Russell-Jones D.L. Insulin detemir, does a new century bring a better basal insulin?. Int. J. Clin. Pract. 59 (2005) 730-739
13. Tracy M.A. Development and scale-up of a microsphere protein delivery system. Biotechnol. Prog. 14 (1998) 108-115
14. Bartus R.T., et al. Sustained delivery of proteins for novel therapeutic agents. Science 281 (1998) 1161-1162
15. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 61 2 Suppl. 1 (2003) 25-31
16. Chu F.M., et al. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J. Urol. 168 (2002) 1199-1203
17. Capon D.J., et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 337 (1989) 525-531
18. Chamow S.M., and Ashkenazi A. Immunoadhesins: principles and applications. Trends Biotechnol. 14 (1996) 52-60
19. Capon, D.J. and Lasky, L.A. [Genentech, Inc.] (1992) Hybrid immunoglobulins. USP5116964
20. Lo, K.M. et al. [Fuji ImmunoPharmaceuticals Corporation] (1996) Expression and export technology of proteins as immunofusins. USP5541087
21. Bitonti A.J., et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. U S A 101 (2004) 9763-9768
22. Low S.C., et al. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum. Reprod. 20 (2005) 1805-1813
23. Dumont J.A., et al. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol. Med. 18 (2005) 294-303
24. Leger R., et al. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg. Med. Chem. Lett. 14 (2004) 4395-4398
25. Jette L., et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 146 (2005) 3052-3058
26. Sung C., et al. An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J. Interferon Cytokine Res. 23 (2003) 25-36
27. Prior, C.P. et al. [Biorexis Pharmaceutical Corporation] (2003) Modified transferrin fusion proteins. US Patent Application 20030221201
28. Prior, C.P. [Biorexis Pharmaceutical Corporation] (2004) Modified transferrin fusion proteins. US Patent Application 20040023334.
29. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1458
30. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 (2003) 214-221
31. Home P., and Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin. Pharmacother. 7 (2006) 325-343
32. Mark M. NN-2211 Novo Nordisk. IDrugs 6 (2003) 251-258
33. Elliott S., et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol. 21 (2003) 414-421
34. Jen A., and Merkle H.P. Diamonds in the rough: protein crystals from a formulation perspective. Pharm. Res. 18 (2001) 1483-1488
35. Basu S.K., et al. Protein crystals for the delivery of biopharmaceuticals. Expert Opin. Biol. Ther. 4 (2004) 301-317
36. Hallas-Møller K., et al. Crystalline and amorphous insulin-zinc compounds with prolonged action. Science 116 (1952) 394-398
37. Hallas-Møller K. The Lente insulins. Diabetes 5 (1956) 7-14
38. Hagedorn H.C., et al. Protamine insulinate. J. Am. Med. Assoc. 106 (1936) 177-180
39. Krayenbuhl C., and Rosenberg T. Crystalline protamine insulin. Rep. Steno Mem. Hosp. Nord. Insulinlab 1 (1946) 60-73
40. DeFelippis M.R., et al. Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue. J. Pharm. Sci. 87 (1998) 170-176
41. Home P.D., and Ashwell S.G. An overview of insulin glargine. Diabetes Metab. Res. Rev. 3 18 Suppl. (2002) S57-S63
42. Cendros J.M., et al. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism 54 (2005) 1276-1281
43. Johnson O.L., et al. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res. 14 (1997) 730-735
44. Johnson O.L., et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. 2 (1996) 795-799
45. Ravivarapu H.B., et al. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int. J. Pharm. 194 (2000) 181-191
46. Dunn, R.L. and Tipton, A.J. [Atrix Laboratories, Inc.] (1997) Polymeric compositions useful as controlled release implants. USP5702716
47. Dunn, R.L. et al. (1990) Biodegradable in-situ forming implants and methods of producing the same. USP4938763